These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34647538)

  • 21. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
    McMurray J; Cohen-Solal A; Dietz R; Eichhorn E; Erhardt L; Hobbs FD; Krum H; Maggioni A; McKelvie RS; Piña IL; Soler-Soler J; Swedberg K
    Eur J Heart Fail; 2005 Aug; 7(5):710-21. PubMed ID: 16087129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
    Fishkind D; Paris BE; Aronow WS
    J Am Geriatr Soc; 1997 Jul; 45(7):809-12. PubMed ID: 9215330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the management of heart failure in primary care.
    Calvert MJ; Shankar A; McManus RJ; Ryan R; Freemantle N
    Fam Pract; 2009 Apr; 26(2):145-53. PubMed ID: 19153098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
    Willenheimer R; Erdmann E; Follath F; Krum H; Ponikowski P; Silke B; Van Veldhuisen DJ; Van De Ven L; Verkenne P; Lechat P;
    Eur J Heart Fail; 2004 Jun; 6(4):493-500. PubMed ID: 15182776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
    Komajda M; Follath F; Swedberg K; Cleland J; Aguilar JC; Cohen-Solal A; Dietz R; Gavazzi A; Van Gilst WH; Hobbs R; Korewicki J; Madeira HC; Moiseyev VS; Preda I; Widimsky J; Freemantle N; Eastaugh J; Mason J;
    Eur Heart J; 2003 Mar; 24(5):464-74. PubMed ID: 12633547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of care in congestive heart failure in the elderly: epidemiological evidence of a gap between guidelines and clinical practice.
    Brocco S; Zamboni M; Fantin F; Marchesan M; Schievano E; Zambon F; Bozzano C; Di Francesco V; Vassanelli C; Spolaore P
    Aging Clin Exp Res; 2010 Jun; 22(3):243-8. PubMed ID: 20634648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
    Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.
    Christie GA; Lucas C; Bateman DN; Waring WS
    Eur J Clin Pharmacol; 2006 Dec; 62(12):989-93. PubMed ID: 17089106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
    Krum H; van Veldhuisen DJ; Funck-Brentano C; Vanoli E; Silke B; Erdmann E; Follath F; Ponikowski P; Goulder M; Meyer W; Lechat P; Willenheimer R;
    Cardiovasc Ther; 2011 Apr; 29(2):89-98. PubMed ID: 20528880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
    Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
    Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing pattern of antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain.
    Sequeira RP; Jassim KA; Damanhori AH; Mathur VS
    J Eval Clin Pract; 2002 Nov; 8(4):407-14. PubMed ID: 12421390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.